摘要
目的探讨乳腺肿瘤激酶(breast tumorkinase,Brk)在非小细胞肺癌(non-small cell lungcancer,NSCLC)的表达及与临床病理因素,Ki67表达之间的关系。方法采用免疫组织化学S-P法检测105例NSCLC及相应癌旁正常肺组织中Brk和Ki67的表达,采用Western Blot方法检测30例新鲜肺癌组织及其癌旁正常肺组织中Brk的表达情况。结果 Western Blot结果显示NSCLC中Brk蛋白表达水平显著高于癌旁正常肺组织(P<0.01)。免疫组织化学结果发现Brk在NSCLN的细胞浆阳性率为51.4%(54/105),明显高于其在癌旁正常肺组织的细胞浆阳性率18.1%(19/105,P=0.003)。Brk在NSCLC细胞浆的阳性表达与肿瘤的大小(P=0.042),淋巴结转移(P=0.012),TNM分期(P=0.042)正相关;Ki67的表达与肿瘤的大小正相关(P=0.033);Brk在细胞浆中的表达与Ki67表达呈正相关(r=0.217,P=0.026)。结论 Brk在NSCLC的细胞表达上调,与肿瘤大小,淋巴结转移,TNM分期正相关;Ki67表达与肿瘤的大小正相关;Brk与Ki67的协同表达可能是促进NSCLC进展的重要因素。
Objective To investigate the expression and correlation of Brk （breast tumor kinase） and Ki67 in non-small cell lung cancer（NSCLC）. Methods The expressions of Brk and Ki67 were examined by immunohistochemistry in 105 NSCLC tissues and Brk protein was detected by Western blot method in 30 fresh NSCLC tissues and the corresponding normal tissues. Results Western Blot results showed that the expression level of Brk protein was significantly higher in NSCLC tissues than in normal lung tissues（P 〈 0.01）, and the immunohistochemistry results showed that the positive rate of Brk was significantly higher in NSCLC cells（S4/105, 51.4%） than in normal lung tissues（19/105, 18.1%, P=0.003）. Brk expression level in NSCLC was positively associated with tumor size（P=0.042）, lymph node metastasis（P=0.012） and advanced TNM stages （P=0.1M2）. Ki67 expression level was positively correlated with tumor size and Brk expression level in NSCLC（r=0.217, P=0.026）. Conclusion The positive synergetic expression of Brk and Ki67 may be involved in tumor progression of NSCLC.
出处
《解剖科学进展》
CAS
2013年第1期9-12,共4页
Progress of Anatomical Sciences
基金
国家自然科学基金资助项目(No.30870977)
